P
OLYCYSTIC OVARY SYNDROME (PCOS) is a heterogeneous endocrine disorder of premenopausal women and the commonest cause of anovulatory infertility and hirsutism (1, 2) . In addition to these important endocrine and reproductive manifestations, PCOS has metabolic characteristics that include prominent defects in both insulin action (3) and ␤-cell function (4). These metabolic derangements are similar to those seen in groups at increased risk of future type 2 diabetes, such as offspring of diabetic parents and women with previous gestational diabetes (5) . Indeed, the frequent co-occurrence of polycystic ovaries and type 2 diabetes strongly suggests shared aetiological determinants underlying the two conditions. There is both a higher incidence of impaired glucose tolerance among women with a past history of PCOS compared with control populations (6, 7) and an increased prevalence of polycystic ovarian morphology in women with frank (8) and gestational (9) diabetes. PCOS, like type 2 diabetes, displays strong familial aggregation (10) . The etiology is multifactorial, individual susceptibility being determined by the action of multiple genetic and environmental risk factors. Studies at the insulin gene are consistent with the hypothesis that shared genetic susceptibility effects contribute to the physiological and epidemiological overlap between type 2 diabetes and PCOS. In both conditions, susceptibility is associated with the paternal transmission of class III insulin-variable number of tandem repeats alleles (11) (12) (13) (14) . On this basis, any gene known to influence susceptibility effects to type 2 diabetes merits evaluation as a candidate for involvement in PCOS.
Recent work has identified the calpain-10 gene (CAPN10) on chromosome 2q37 as such a candidate. This chromosomal region was initially highlighted in a genome-wide scan for linkage to type 2 diabetes conducted in Mexican-American families (15) . Subsequent positional cloning efforts (16, 17) revealed that variants in the CAPN10 gene displayed the most robust associations with diabetes and were uniquely able to account for the original evidence for linkage. In Mexican-Americans, SNP-43 was the variant most strongly associated with the evidence for linkage (17) . However, inclusion of genotype data from other CAPN10 polymorphisms strengthened the association with type 2 diabetes in both Abbreviations: CAPN10, Calpain-10 gene; HDL, high density lipoprotein; PCOS, polycystic ovary syndrome; SNP, single nucleotide polymorphism.
Mexican-American and European populations (17, 18 ). It appears that CAPN10-encoded susceptibility to type 2 diabetes is best described in terms of haplotypes including several different polymorphic sites. It has been estimated that variation within CAPN10 explains 14% of type 2 diabetes risk in Mexican-Americans. Studies that have sought replication of these associations in other populations have produced somewhat conflicting results, with some reports strongly positive (19, 20) , others providing more guarded support (21) (22) (23) , and others negative (24, 25) .
The biological mechanisms relating variation in expression or function of CAPN10, a ubiquitously expressed protease (26, 27) , to the development of type 2 diabetes, remain to be determined. Neither is it known whether the susceptibility effects of CAPN10 variation extend to other phenotypes associated with diabetes and insulin resistance. In this study, we have used both family based and case-control methodologies to explore the relationship between variation in the CAPN10 gene and the development of polycystic ovarian syndrome.
Materials and Methods Subjects
Cases. All subjects in this study were of European, predominantly (Ͼ80%) British, ancestry. Women with PCOS (n ϭ 331) were ascertained from infertility and endocrine clinics at St. Mary's and the Middlesex Hospitals (London, UK). The criteria for diagnosis of PCOS were as previously described (10) and rely on the combination of clinical symptoms, ultrasonographic examination, and biochemical data. The essential criteria for the diagnosis of PCOS in the proband were the presence of polycystic ovaries on ultrasound in a patient presenting with hyperandrogenism (hirsutism, acne and/or elevated serum T) and/or symptoms of anovulation (amenorrhoea or oligomenorrhoea). For 146 of these 331 women (designated probands), DNA was available from both parents such that parent-offspring trios could be generated: the remaining 185 without parental DNA are designated PCOS cases. Family relationships in the trios were confirmed by genotyping with a panel of highly polymorphic microsatellite markers (combined heterozygosity Ͼ99%). Clinical characteristics are given in Table 1 . All subjects gave fully informed consent.
Population sample (control subjects). Population allele and haplotype frequencies for the case-control analyses were derived from a populationbased sample of 525 British Europid subjects. These represent cord bloods from a consecutive series of unrelated births, collected as part of the EarlyBird Study Cohort (Plymouth, UK) as described elsewhere (28) .
Assays. In all PCOS women, fasting samples were used for the analysis of plasma cholesterol, high density lipoprotein (HDL)-cholesterol, triglycerides, insulin, and glucose. Glucose and lipids were measured enzymatically on an AU5200 analyzer (Olympus Corp. Opticals UK Ltd., London, UK). Selective precipitation of non-HDL lipoproteins using dextran sulfate and magnesium was used to assay levels of HDL-cholesterol. Insulin levels were measured by ELISA (29) . Androstenedione, 17-hydroxyprogesterone, dihydrotestosterone, and T were measured using in-house RIAs employing ether extraction and dextran-coated charcoal separation. Mean coefficients of variation were Ͻ10% for androstenedione and 17-hydroxyprogesterone and Ͻ15% for dihydrotestosterone. SHBG was measured using the Immulite method (Diagnostic Products, Llanberis, UK) (1, 30) . Genomic DNA was extracted from whole blood using the PUREGENE kit (Gentra Systems, Minneapolis, MN) as described previously (31) .
Single nucleotide polymorphism (SNP) genotyping. For this study, four CAPN10 variants were typed. Three of these (SNP-43; SNP-19; SNP-63) define the high-risk haplotypes for diabetes susceptibility in MexicanAmerican and two Northern European populations (from Botnia, Finland and Saxony, Germany) (17) . The fourth (SNP-44), which lies 11 bp proximal to SNP-43, was included on the basis of: 1) proven functional effects on CAPN10 expression (17); and 2) data suggesting that SNP-44 might play an independent type 2 diabetes-susceptibility role in British families (21) .
Details of typing methods for these SNPs are provided in Table 2 . SNP-44 (CAPN10-g.4841T/C) and SNP-43 (CAPN10-g.4852G/A) were typed using mutagenically separated PCR assays that employ one common and two size-differentiated allele-specific primers. Nucleotide mismatches were introduced to improve allele specificity where necessary (32) and allelespecific primer concentrations adjusted to compensate for the different PCR efficiencies of the two amplifications (typically, a ratio of long to short primer of 15:1). SNP-63 (CAPN10-g.1637C/T) was typed using a forced HhaI (New England Biolabs, Inc., Beverly, MA) PCR-restriction fragment length polymorphism assay. SNP-19 (CAPN10-g.7920indel32bp) is, in fact, a 32-bp insertion/deletion polymorphism and was typed directly after PCR amplification.
In all cases, PCR were carried out in a total volume of 20 l containing 5% dimethylsulfoxide vol/vol; 0. All PCRs were analyzed by polyacrylamide microplate diagonal gel electrophoresis (33) . Alleles are labeled in line with the nomenclature previously devised (17) . Thus, allele 1 corresponds to allele G for SNP-43, allele T for SNP-44, allele C for SNP-63, and to the deletion allele for SNP-19.
Statistical analyses
In the parent-offspring trios, single and multilocus transmission disequilibrium analyses (34) were performed using the TRANSMIT software (35, 36) . Proportions of heterozygous parents and percentage transmissions from heterozygous parents were derived from the TRANSMIT output, under the assumption of Hardy-Weinberg equilibrium. When computing global tests for the multilocus analyses, all rare haplotypes (frequency Ͻ5%) were pooled.
The primary analysis of the single-locus case-control data applied the Kruskal-Wallis test to individual genotypes, exact significance values being obtained using STATXACT (Cytel, Cambridge, MA). For casecontrol analyses comparing haplotype frequencies, we performed likelihood-ratio tests based on the haplotype frequency likelihoods derived from TRANSMIT. Due to the low numbers of observations of certain haplotypes (making asymptotic assumptions invalid) empirical significance values were determined from 20,000 permutations of case/control status and likelihood recalculation.
Haplotype counts for estimation of the odds ratios for the high-risk haplotype (112/121 at SNP-43, -19, and -63) (17) were derived from phased (trios) and nonphase (cases and controls) genotype data, the latter on the assumption that all individuals homozygous at SNP-43 and Median (and inter-quartile range) values for age, body mass index, and WHR are shown. The subdivision of PCOS subjects into probands and cases is based on the availability of parental DNA.
heterozygous at SNP-19 and SNP-63 carried this configuration. The low frequency of the 122 haplotype in Europeans means this is true in Ͼ90% of such individuals. Similar assumptions were used to estimate absolute haplotype counts for odds ratio analyses for other observed genotype combinations. Significance testing of the odds ratio was performed using exact probabilities implemented by STATXACT.
Results

Single-locus analyses
Genotypes at all loci were in Hardy-Weinberg equilibrium with the exception of a marginal departure (uncorrected P ϭ 0.045) seen in PCOS cases at SNP-44. Results from the singlelocus transmission disequilibrium tests of CAPN10 variants in the 146 trios are shown in Table 3 . No deviations from Mendelian expectation were detected at SNP-44 (54.9% transmission of allele 1; P ϭ 0.38); SNP-43 (51.3% transmission; P ϭ 0.78); or SNP-19 (46.7% transmission, P ϭ 0.44). At SNP-63, there was nominally significant excess transmission of the common allele from heterozygous parents to PCOS offspring (67.2% transmission; P ϭ 0.03). However, singlelocus tests in the independent case-control cohort of 185 cases and a population sample of 525 subjects (Table 4) revealed no association at any of the variants. In particular, there were no genotype (P ϭ 0.62) or allele (P ϭ 0.73) frequency differences at SNP-63, nor was there evidence for association at SNP-63 when all PCOS subjects (cases and probands, n ϭ 331) were included in the case-control comparison (genotype-wise P ϭ 0.64; allele-wise P ϭ 0.56).
Multilocus analyses
We observed strong linkage disequilibrium between these variants (P Ͻ 0.001), and significantly reduced haplotype diversity ( Table 5 ). Five of the 16 possible haplotypes accounted for Ͼ98% of all chromosomes observed, reflecting the haplotype distribution previously observed in other European populations (17, 21) . Compared with Mexican-American and Asian populations (17) , European populations show more (43-19-63) 111 haplotypes (0.31 in our UK population sample compared with 0.17 in Mexican-Americans, 0.08 in Chinese and 0.14 in Japanese) and fewer 112 haplotypes (0.07 in the UK vs. 0.23 in Mexican-Americans, 0.31 in Chinese, and 0.25 in Japanese).
Comparison of haplotype frequencies between probands and control subjects suggested a preponderance of 1111 haplotypes in the probands (Table 5 ), but the empirical significance of the proband vs. control comparison was not significant (P ϭ 0.082; 20,000 replicates). No association was observed in the comparison of cases and controls (P ϭ 0.40), nor when all (n ϭ 331) PCOS individuals were pooled and compared with control subjects (P ϭ 0.097). Neither was any significant excess transmission of 1111 (or any other haplotype) observed using the multilocus family based association studies in the trios (Table 6 : global chisquare ϭ 7.68. df5, P ϭ 0.18).
In both Mexican-Americans and Northern Europeans (Finnish and German), the 112/121 (SNP-43, -19, -63) multilocus genotype has been reported as displaying the highest risk, approximately 3-fold, for type 2 diabetes (17) . There was no evidence that this haplotype combination was associated with an increased risk for PCOS in our data set (odds ratio 0.84 (95% CI 0.40 -1.71) for pooled PCOS cases and probands vs. control subjects, P ϭ 0.61). In fact, no haplotype combination (of the fifteen possible derived from the five common haplotypes) was associated with an increased odds ratio for In the primer sequences provided, italics indicate bases deliberately mismatched to improve allele specificity, and uppercase in SNP63 denotes the nucleotide modified to create an artificial HhaI site. For other details, see text.
PCOS, the only nominally significant result being obtained for the 2111/2111 genotype [odds ratio 0.12 (0.02-0.82), P ϭ 0.019].
Intermediate trait analysis
To detect any relationship between CAPN10 variation and intermediate and quantitative traits relevant to the pathogenesis of type 2 diabetes and PCOS, we looked for genotype-dependent differences within the PCOS subjects. Variables considered included anthropometric (BMI, waist-hip ratio); metabolic (fasting glucose, fasting insulin, total and HDL cholesterol, triglycerides); and endocrine (testosterone, androstenedione, LH, FSH) parameters. No association with genotype was observed at any of the CAPN10 variants (data not shown).
Discussion
In this study of variation in the CAPN10 gene, we have been unable to detect any consistent evidence for association with PCOS or any of the subphenotypes examined, leading us to conclude that variation within this gene does not play a significant role in susceptibility to PCOS, in this population at least. Although we found nominal association with one variant (SNP-63) in the family-based association tests, this was clearly not confirmed in other analyses. Given the increasing, but as yet inconclusive, evidence supporting the association between CAPN10 variation and type 2 diabetes (17) (18) (19) (20) (21) (22) (23) (24) (25) 37) , there are a number of possible reasons for our failure to detect association.
The most likely explanation is that, although variation within the CAPN10 gene may influence susceptibility to type 2 diabetes, it has no influence on PCOS risk. The physiological and epidemiological overlap between PCOS and type 2 diabetes suggests shared etiological mechanisms, and studies of the insulin gene indicate that some of these shared mechanisms are inherited (11) (12) (13) (14) . However, in these multifactorial conditions with related but distinct phenotypic patterns, complete concordance of susceptibility effects would not be expected. The mechanisms whereby altered function or regulation of CAPN10 produces type 2 diabetes are unknown, but there are suggestions that this protease plays a role in normal insulin secretion (38 -41) . If confirmed, this would be entirely consistent with defective CAPN10 function having a more marked influence on susceptibility to type 2 diabetes than PCOS.
The second related explanation is that our analysis failed to detect a CAPN10 effect on PCOS because it is of modest magnitude and our study lacked the power to detect it. It is clear (42) that very large studies (or meta-analyses of several smaller studies) are needed if alleles of modest effect (relative risks of less than 1.2) are to be completely excluded from a role in disease susceptibility. Certainly, variation at the CAPN10 gene seems to have a lesser effect on susceptibility to type 2 diabetes in Europeans than Mexican-Americans, presumably due to ethnicity-related differences in the frequency of risk-associated haplotypes (17) and of modifier genotypes at other loci (16) .
A further possibility is that additional CAPN10 variants are involved in disease-susceptibility. Though we have not conducted a comprehensive analysis of all variants in and around the CAPN10 gene and cannot exclude the role of other variants outside this region, on the available evidence the four variants typed provide the best explanation of susceptibility to type 2 diabetes in European populations (17, 21, 43) . Extensive mutational screening of the gene (17, 21) , the observation that linkage disequilibrium declines rapidly away from the CAPN10 locus (17) , and demonstrable functional correlates of several of these variants (17) , combine to suggest that some, at least, play a direct role in disease pathogenesis (18) . However, until the inventory of sequence variation in the CAPN10 region in European subjects is complete, it remains conceivable that future work will identify additional disease susceptibility genes or variants, refining and improving our capacity to detect genotype-phenotype correlations to diabetes and related conditions such as PCOS.
The data presented by Horikawa and colleagues (17) suggest a model for CAPN10-related disease susceptibility whereby disease risk is greatest in individuals inheriting different CAPN10 haplotypes from each parent. Although such a model might be expected to reduce the power of transmission disequilibrium analyses, the use of both familybased and case-control methodologies in our study, should help to overcome any possible consequences (44) .
In summary, therefore, this study provides no evidence that variation in the CAPN10 gene influences susceptibility to PCOS. Given the accumulating (but not conclusive) evidence that CAPN10 variation influences susceptibility to type 2 diabetes, these data may indicate that CAPN10 acts via pathways that are not common to the two conditions. However, we note that robust evaluation of the role of variants of modest effect in influencing susceptibility to common multifactorial diseases (such as PCOS and type 2 diabetes) remains a challenging task. Definitive confirmation that CAPN10 gene variation has absolutely no effect on PCOS susceptibility will ultimately require studies incorporating thousands rather than hundreds of subjects. Frequencies are shown for the five major CAPN10 haplotypes identified in our data. Empirical significance for comparison of probands and controls, P ϭ 0.082; for cases and controls, P ϭ 0.40; for pooled PCOS subjects and controls, P ϭ 0.097. Analyses using TRANSMIT of the haplotypes formed from the four variants in CAPN10 studied. Global analysis of all haplotype transmissions yielded a chisquare statistic of 7.68 (df5, P ϭ 0.18).
a Percentage of the 292 parents heterozygous for this haplotype.
